More Articles

Report on 25th Annual EuroMeeting, 4-6 March 2013, Amsterdam, The Netherlands Conferences | Posted 05/04/2013

Delegates at DIA’s 25th Anniversary of the EuroMeeting, held on 4–6 March 2013 in Amsterdam, The Netherlands, were offered the mouth watering prospect of more than 100 sessions across 17 themes, ad...

Biosimilars in rheumatology Biosimilars/Research | Posted 29/03/2013

Patents on key biological medicines used in rheumatology will expire soon. The European Medicines Agency’s (EMA’s) finalized guidelines on biosimilar monoclonal antibodies (mAbs) came into effect o...

US state biosimilar substitution bill becomes law Policies & Legislation | Posted 29/03/2013

On 21 March 2013, the US State of Virginia signed into law a legislation allowing for the substitution of biosimilars, but with many restrictions, making it the first US state to introduce such leg...

Why choose generic medicines initiative launched in Australia Generics/General | Posted 29/03/2013

The Australian Generic Medicines Industry Association (GMiA) and the Pharmacy Guild of Australia announced on 22 March 2013 the launch of a joint initiative: Why choose generic medicines?

Sandoz’s biosimilar rituximab on track Biosimilars/News | Posted 29/03/2013

The development of a biosimilar version of Rituxan (rituximab) is proceeding as planned, Sandoz’s Global Head, Mr Jeff George told Bloomberg.

Use of generic medicines in Ireland Generics/Research | Posted 29/03/2013

Ireland’s Department of Health and Children intends to introduce a system of reference pricing and generics substitution in Ireland, which will greatly increase the utilization of generics and gene...

Brand-name drug and generics makers fight to save pay-for-delay Policies & Legislation | Posted 29/03/2013

Brand-name drug and generics manufacturers are joining forces to fight against the US Federal Trade Commission (FTC) in the case of reverse patent settlements or ‘pay-for-delay’, as the FTC terms t...

Guideline update on prevention of febrile neutropenia with G-CSF Guidelines | Posted 29/03/2013

Patients undergoing chemotherapy for cancer are at risk of developing the sometimes fatal condition of febrile neutropenia (FN), involving infection, fever and sepsis due to a loss of neutrophils....